A potential therapy studied by the Oldstone Lab may stop type 1 diabetes from progressing past the prediabetic stage.
Findings from the Paulson Lab could guide vaccine design.
"Ron's business acumen and philanthropic mindset will be critical to realizing the new self-sustaining 'bench-to-bedside' model we are building," said Peter G. Schultz, Ph.D., President of TSRI and the California Institute for Biomedical Research (Calibr).